Il.

12.

The FFD evaluation included laboratory testing, the results of which are
available to the Respondent.

On April 8, 2019, the Hospital terminated the Respondent’s employment.

On or about July 31, 2019, Board staff sent an initial contact letter notifying the
Respondent that a full investigation had been opened and requesting a written
response within ten business days.

On or about August 14, 2019, Board staff received the Respondent’s written
response and other materials as directed by the initial contact letter. In her written
response, the Respondent stated that her termination was “a direct result of a
momentary lapse in judgement.” The Respondent elaborated that she “made the
absolute worst decision [she] could have made, which was to self-medicate with
an illicit substance...” The Respondent went on to state that she did not take the
substance while she was at work but that she did go to work while it was still in
her system and put herself and her patients at risk.

On or about November 5, 2019, Board staff conducted an interview of the
Respondent under oath.

The Respondent stated that she was terminated because she used an illicit
substance and made the mistake of going into work. She stated that on the night
prior to reporting to work on the morning of March 26, 2019, she purchased what

she believed to be Percocet’ and consumed it via insufflation sometime between

* Oxycodone acetaminophen, commonly sold under the brand name Percocet inter alia, is an opioid pain medication
that is classified as a Schedule II CDS.
